Table 6 Antitumour activity of XELIRI – best response

From: A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

Dose level

Irinotecan (mg m−2)

Capecitabine (mg m −2 twice daily)

CR

PR

Stable disease

Progressive disease

1 (n=3)

200

700

   

3

2 (n=3)

200

850

   

3

3 (n=4)

200

1000

  

1

3

4 (n=8)

250

1000

1a

 

2

5

5 (n=5)

250

1150

 

1b

1

3

Total (n=23)

  

1

1

4

17

  1. CR=complete response; PR=partial response.
  2. aPatient with colorectal cancer (CRC) who had previously demonstrated a partial response to 5-FU/oxaliplatin.
  3. bPatient with CRC who had previously demonstrated PR and CR, as well as disease stabilisation, after treatment with three previous 5-FU-based regimens.
Back to article page